GENE ONLINE|News &
Opinion
Blog

FDA Allows Marketing of New Device to Reduce Nightmare-Related Sleep Disturbances in Adults

by GeneOnline
Share To

The US Food and Drug Administration (USFDA) has allowed the marketing of a new sleep-disturbing device for temporary nightmares in adults 22 years and older with nightmares or post-traumatic stress disorders (PTSDs). The device offers gentle touch vibration based on an analysis of cardiac rates and sleep movement.

“Sleep is an essential part of a person’s daily routine. However, certain adults who have a nightmare disorder or who experience nightmares from PTSD are not able to get the rest they need,” said Carlos Peña, Ph.D., director of the Department of Neurology and Physical Medicine at the FDA Devices and Radiological Health Centre. “Today’s authorization offers a new, low-risk treatment option that uses digital technology in an effort to provide temporary relief from sleep disturbance related to nightmares.”

PTSD is a disorder in some people who have experienced a shocking, frightening, or dangerous occurrence. People may have experienced a number of trauma reactions from which they will recover over time. However, PTSD is diagnosed with those who continue to experience symptoms that may include sleep problems and nightmares. Several drugs may help address specific symptoms of PTSD. Besides, an experienced mental health professional can help people find a treatment plan that meets their symptoms and needs.

The Nightware is an Apple Watch and Apple iPhone digital therapy device that is configured and logged in to a Nightware software application and server. The Apple Watch sensors monitor cardiovascular movement and heart rate during sleep. These are forwarded to the Nightware server, and the device uses a proprietary algorithm to create a unique patient sleep profile. Based on cardiac rate and body motion analysis, vibrations are delivered using the Apple Watch when detecting a patient suffering from a nightmare. Nightware is available on prescription only and is for home use only.

This device was studied in a randomized, sham-controlled study of 70 patients for 30 days. Sham therapy is an inactive treatment or procedure designed to imitate therapy in a clinical trial as closely as possible. Patients in the sham group had worn the devices, but no vibrational stimulations were provided. Safety was evaluated with validated suicidality and sleep measurements, and no changes occurred in either group during the course of the study. The assessment of sleep was carried out using two versions of the Pittsburgh Sleep Quality Index, a self-rated evaluation of sleep quality questionnaire, with a scale version intended for PTSD patients. Both the sham and the active groups showed improvement in sleeping scales, with the active group showing greater improvement. Evidence shows that the likely advantages outweigh the likely risks.

By Ching-Hsu Yang, Ph.D. Candidate, National Taiwan University

Editor: Rajaneesh K. Gopinath, Ph.D.

Related Article: Can Your Smartwatch Help You Manage Asthma Better?

References
  1. https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-new-device-designed-reduce-sleep-disturbance-related-nightmares-certain-adults
  2. https://www.apple.com/tw/watch/?afid=p238%7CspoMq4twe-dc_mtid_18707vxu38484_pcrid_465660578624_pgrid_16718749022_&cid=aos-tw-kwgo-watch–slid—product–
  3. https://night-ware.com/

 

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
R&D
Advancements in Alzheimer’s Disease Drug Innovation and Funding Programs in 2024
2024-07-04
FDA Greenlights Eli Lilly’s Groundbreaking Alzheimer’s Drug Kisunla for Early Symptomatic Treatment
2024-07-04
Tanvex BioPharma Secures Asia’s First FDA Approval for Filgrastim Biosimilar, Seizing a $403 Million Market
2024-07-03
LATEST
Topo-1 and FRα: Key Focus Areas and Major Collaborations in ADC Research – Part I
2024-07-23
Eli Lilly’s Tirzepatide Gets Approval in China for Weight Loss Management
2024-07-22
Roche Reports Positive Clinical Trial Results for Two Diabetes-Related Eye Disease Therapies
2024-07-19
7th Person in History Possibly Cured From HIV After Stem Cell Transplant for Acute Myeloid Leukemia
2024-07-19
Large RCT Finds Time-Lapse Imaging for Embryo Selection in IVF Does Not Improve Live Birth Rates
2024-07-19
Assessment of Supply Chain Risk Key to Improving Medicine Access
2024-07-18
SK Biopharma and Full-Life Sign US$571.5 Million Deal for Innovative Radiopharmaceutical FL-091
2024-07-18
EVENT
Scroll to Top